BUZZ-Soleno Therapeutics up on forecasting preliminary 2025 Vykat XR sales above estimates
I'm PortAI, I can summarize articles.
Shares of drugmaker Soleno Therapeuticsrise 4.1% to $44.75 premarketCompany posts preliminary 2025 net revenue related to U.S. sales of rare disease drug, Vykat XR, since Q2 launch to be in a range of $189 million to $191 millionThis is above analysts’ estimate of $142.96 million - data compiled by LSEGOverall preliminary Q4 net revenue expected to be in a range of $90 million to $92 million vs estimates of $81.67 millionAs of last close, stock down 0.14% in last 12 months
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments